Data From Phase 2 Trials of ELX-02 Expected This Year

Data From Phase 2 Trials of ELX-02 Expected This Year

298702

Data From Phase 2 Trials of ELX-02 Expected This Year

Eloxx Pharmaceuticals announced it expects to share data later this year from the first four treatment groups of a Phase 2 program evaluating the investigational therapy ELX-02 in people with cystic fibrosis (CF) who have at least one G542X mutation. “Given the substantial efforts of our clinical team, we have made considerable progress in enrolling patients in our ongoing Phase 2 clinical program to explore the potential of ELX-02 to treat cystic fibrosis. Given this progress,…

You must be logged in to read/download the full post.